Workshop on Immune Reconstitution after Stem Cell Transplantation
Friday, April 26th, 2002
Building 10, Masur Auditorium, National Institutes
of Health, Bethesda, MD
Sponsored by the National Heart, Lung, and Blood
Institute and the Department of Transfusion Medicine, NIH
The purpose of this workshop is to review the uses of
adoptive cellular immune therapy and methods available to evaluate the effects
of these therapies. The success of hematopoietic transplants is dependent on
the reconstitution of the donor's cellular immune response. Donor cellular
immunity must be brisk enough to protect the host from viral infections and to
prevent disease relapse, but not so brisk as to cause graft-versus-host
disease. In some cases after transplant, the recipient is given either
unmanipulated or manipulated donor lymphocytes to treat Epstein Barr virus
(EBV) or cytomegalovirus (CMV) infection or induce a graft-versus-leukemia or
graft-versus-tumor effect. In addition, some hematologic malignancies and other
cancers are being treated with manipulated T cells or with cellular vaccines
designed to induce tumor-directed cytotoxicity. While the use of the novel
cellular transfusion products is expanding, the monitoring and assessment of
these interventions has been inconsistent. This workshop will review current
approaches to studying immune reconstitution after stem cell transplantation
and identify areas of research in need of research support and development.
Agenda
Time
Topic
Speaker
8:00-8:10
a.m.
Welcome
Liana
Harvath
Biology of Immune
Reconstitution
Moderator: H. Heslop
8:10-8:30
a.m.
Immunologic basis of the
alloresponse
John
Barrett
8:30-8:50
a.m.
B cell immune reconstitution after allogeneic
transplants
Jan Storek
8:50-9:10
a.m.
T cell immune reconstitution after allogeneic
transplants
Dan Douek
9:10-9:30
a.m.
Enhancing immune reconstitution after transplants with
cytokines Crystal Mackall
9:30-9:50
a.m. Break
9:50-10:10
a.m.
Donor Th2 cells for the prevention of
GvHD
Dan Fowler
10:10-10:30
a.m. Suicide
genes to prevent
GvHD
Richard O'Reilly
10:30-11:10
a.m. Panel
Discussion
Enhancing the Immune
Response
Moderator: J. Barrett
11:10-11:30
a.m.
Immune therapy for EBV
infections
Helen
Heslop
11:30-11:50
a.m.
Immune therapy for CMV
disease
H. Einsele
11:50-1:00
p.m. Lunch
1:00-1:20
p.m.
Immune therapy for
AML
Jeff
Molldrem
1:20-1:40
p.m.
Immune therapy for B cell
malignancies
John
Gribben
1:40-2:00
p.m.
Naked DNA modified T cells to treat
lymphoma
Mike Jensen
2:00-2:20
p.m.
NK allorecognition: biology and clinical application in
transplants Michael Caliguri
2:20-2:40
p.m. Break
2:40-3:00
p.m.
Minor antigens and
GvL
Stan
Riddell
3:00-3:30
p.m.
Panel Discussion
Regulatory
Issues
Moderator:
E. J. Read
3:30-3:50
p.m.
What a cell processing lab can and can't do for immune
therapy Adrian Gee
Adoptive Immune Therapy, the FDA, and
You
3:50-4:10
p.m.
A regulatory approach to donor derived lymphocytes:
Current
considerations.
Ellen
Lazarus
4:10-4:20
p.m.
A regulatory framework for manipulated cellular
products
Donald Fink
4:20-4:50
p.m. Panel
Discussion
To register, e-mail or telephone
any of the following:
Liana Harvath, Ph.D., NHLBI
harvathl@nhlbi.nih.gov,
301-435-0063
Traci Mondoro, Ph.D., NHLBI,
mondorot@nhlbi.nih.gov,
301-435-0052
David Stroncek, M.D., CC DTM
dstroncek@mail.cc.nih.gov
|